News >

VCD Induction Induces High Response Rates in Myeloma

Jason Harris
Published: Thursday, Oct 12, 2017

Hermann Einsele, MD

Hermann Einsele, MD
Induction therapy with bortezomib (Velcade), cyclophosphamide, and dexamethasone (VCD) induced strong response rates in treatment-naïve patients with multiple myeloma, according to phase II results from the DSMM XI trial published in the British Journal of Haematology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x